| Pharmaceutical Information |
| Drug Name |
Teriparatide |
| Drug ID |
BADD_D02166 |
| Description |
Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company. |
| Indications and Usage |
For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. |
| Marketing Status |
approved; investigational |
| ATC Code |
H05AA02 |
| DrugBank ID |
DB06285
|
| KEGG ID |
D06078
|
| MeSH ID |
D019379
|
| PubChem ID |
16133850
|
| TTD Drug ID |
D0YA2L
|
| NDC Product Code |
14403-0013; 41524-0010; 52221-119; 69766-088; 65129-1312; 0002-8400; 68594-030; 47781-652; 32861-0008 |
| UNII |
10T9CSU89I
|
| Synonyms |
Teriparatide | hPTH (1-34) | Human Parathyroid Hormone (1-34) | Parathar | Teriparatide Acetate | Forteo |
|
| Chemical Information |
| Molecular Formula |
C181H291N55O51S2 |
| CAS Registry Number |
52232-67-4 |
| SMILES |
CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC(
CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C(
=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)N
C(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC
(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)
O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)N
C(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
